Long-term Outcome of Risankizumab in Crohn’s Disease: a Real-world GETAID Study
Clinical Gastroenterology and Hepatology · 2024-12 · 22 (12) · 2451-2458.e1
DOI: 10.1016/j.cgh.2024.04.016 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Clinical Gastroenterology and Hepatology, 2024-12. Verfasst von Mathurin Fumery und 28 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Amiens University hospital, and PeriTox, Université de Picardie, France. Electronic address: fumery.mathurin@chu-amie…. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Crohn Disease. Die Arbeit wurde bisher 38-mal zitiert (Crossref) und nennt 13 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, Amiens University hospital, and PeriTox, Université de Picardie, France. Electronic address: fumery.mathurin@chu-amiens.fr.
- Department of Gastroenterology, Nancy University Hospital, Vandœuvre-lès-Nancy, France and INSERM, NGERE, University of Lorraine, F-54000 Nancy, France and INFINY Institute, Nancy University Hospital, F-54500 Vandœuvre-…
- Department of Gastroenterology and Clinica Nutrition, CHU of Nice, Nice, France and University Côte d'Azur, Nice, France.
- Department of Gastroenterology, CHU de Montpellier, France.
- Department of Gastroenterology, CHU de Saint-Etienne, France.
- Institut des MICI, Clinique Ambroise Paré-Hartmann, Neuilly-sur-Seine, France.
Zitieren
APA
Fumery, M., Caron, B., Hébuterne, X., Altwegg, R., Roblin, X., Stefanescu, C., Meyer, A., Nachury, M., Laharie, D., Le Berre, C., Guillo, L., Biron, A., Caillo, L., Buisson, A., Nancey, S., Uzzan, M., Vuitton, L., Gilletta, C., Geyl, S., …, & Peyrin-Biroulet, L. (2024). Long-term Outcome of Risankizumab in Crohn’s Disease: a Real-world GETAID Study. Clinical Gastroenterology and Hepatology, 22(12), 2451-2458.e1. https://doi.org/10.1016/j.cgh.2024.04.016
Vancouver
Fumery M, Caron B, Hébuterne X, Altwegg R, Roblin X, Stefanescu C, et al. Long-term Outcome of Risankizumab in Crohn’s Disease: a Real-world GETAID Study. Clinical Gastroenterology and Hepatology. 2024;22(12):2451-2458.e1. doi:10.1016/j.cgh.2024.04.016
BibTeX
@article{Fumery2024,
author = {Fumery, Mathurin and Caron, Benedicte and Hébuterne, Xavier and Altwegg, Romain and Roblin, Xavier and Stefanescu, Carmen and Meyer, Antoine and Nachury, Maria and Laharie, David and Le Berre, Catherine and Guillo, Lucas and Biron, Amélie and Caillo, Ludovic and Buisson, Anthony and Nancey, Stephane and Uzzan, Mathieu and Vuitton, Lucine and Gilletta, Cyrielle and Geyl, Sophie and Blain, Antoine and Kirchgesner, Julien and Ah-Soune, Philippe and Duveau, Nicolas and Vidon, Mathias and Abitbol, Vered and Paupard, Thierry and Tran-Minh, My-Linh and Defrance, Antoine and Peyrin-Biroulet, Laurent},
title = {Long-term Outcome of Risankizumab in Crohn’s Disease: a Real-world GETAID Study},
journal = {Clinical Gastroenterology and Hepatology},
year = {2024},
volume = {22},
number = {12},
pages = {2451--2458.e1},
doi = {10.1016/j.cgh.2024.04.016}
}
EUVIMED